ebomi
Colour theme
Sign in
Insider · CIK 0001559827

Florence Anthony A. Jr.

CIK 0001559827 Name as filed on the most recent filing

Filed as Florence Anthony A. Jr. (92)

147 transaction lines · from 92 filings · filed 2014-08-06 to 2026-03-12 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

98 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2021-12-21 S, Open-market sale Imara Inc.IMRA 95,804, disposed Open Form 4 filing 0001209191-21-071262
2021-12-20 S, Open-market sale Imara Inc.IMRA 2 lines 192,604, disposed Open Form 4 filing 0001209191-21-071262
2021-12-16 S, Open-market sale Imara Inc.IMRA 100,546, disposed Open Form 4 filing 0001209191-21-071262
2021-12-15 S, Open-market sale Imara Inc.IMRA 65,685, disposed Open Form 4 filing 0001209191-21-071262
2021-12-14 S, Open-market sale Imara Inc.IMRA 38,643, disposed Open Form 4 filing 0001209191-21-071262
2021-12-13 S, Open-market sale Imara Inc.IMRA 49,558, disposed Open Form 4 filing 0001209191-21-071262
2021-12-10 S, Open-market sale Metacrine, Inc.MTCR 49,630, disposed Open Form 4 filing 0001209191-21-071269
2021-12-10 S, Open-market sale Imara Inc.IMRA 24,541, disposed Open Form 4 filing 0001209191-21-071262
2021-12-09 S, Open-market sale Imara Inc.IMRA 16,693, disposed Open Form 4 filing 0001209191-21-071262
2021-10-18 P, Open-market purchase Trevi Therapeutics, Inc.TRVI Not reported Open Form 4 filing 0001209191-21-061094
2021-06-28 P, Open-market purchase Bright Health Group Inc.BHG 2 lines 34,999,992, acquired Open Form 4 filing 0001209191-21-044192
2021-06-28 P, Open-market purchase Monte Rosa Therapeutics, Inc.GLUE 19,950,000, acquired Open Form 4 filing 0001209191-21-044040
2021-04-13 P, Open-market purchase Reneo Pharmaceuticals, Inc.RPHM 9,999,990, acquired Open Form 4 filing 0001209191-21-026862
2021-03-16 P, Open-market purchase Marker Therapeutics, Inc.MRKR 9,999,999, acquired Open Form 4 filing 0001209191-21-021813
2020-12-04 P, Open-market purchase Regulus Therapeutics Inc.RGLS 2,735,930, acquired Open Form 4 filing 0001209191-20-061968
2020-10-20 P, Open-market purchase Eargo, Inc.EAR 5,599,998, acquired Open Form 4 filing 0001209191-20-055618
2020-09-18 P, Open-market purchase Metacrine, Inc.MTCR 9,999,990, acquired Open Form 4 filing 0001209191-20-051529
2020-07-28 P, Open-market purchase Inozyme Pharma, Inc.INZY 4,000,000, acquired Open Form 4 filing 0001209191-20-043882
2020-07-24 P, Open-market purchase Genocea Biosciences, Inc.GNCA 7,090,335, acquired Open Form 4 filing 0001209191-20-043867
2020-07-14 P, Open-market purchase Nkarta, Inc.NKTK 11,999,988, acquired Open Form 4 filing 0001209191-20-042650
2020-06-30 P, Open-market purchase Akouos, Inc.AKUS 9,999,995, acquired Open Form 4 filing 0001209191-20-039828
2020-06-19 P, Open-market purchase Aveo Pharmaceuticals, Inc.AVEO 7,499,998, acquired Open Form 4 filing 0001209191-20-038238
2020-05-20 S, Open-market sale Surface Oncology, Inc.SURF 1,535,562, disposed Open Form 4 filing 0001209191-20-031786
2020-04-13 S, Open-market sale Mersana Therapeutics, Inc.MRSN 177,775, disposed Open Form 4 filing 0001209191-20-024292
2020-04-03 S, Open-market sale Trevi Therapeutics, Inc.TRVI 1,500, disposed Open Form 4 filing 0001209191-20-024285
2020-03-16 P, Open-market purchase Imara Inc.IMRA 7,600,000, acquired Open Form 4 filing 0001209191-20-019337
2020-03-06 S, Open-market sale Champions Oncology, Inc.CSBR 4,950,003, disposed Open Form 4 filing 0001209191-20-017699
2020-02-10 P, Open-market purchase Casper Sleep Inc.CSPR 15,000,000, acquired Open Form 4 filing 0001209191-20-008758
2020-01-24 P, Open-market purchase Adaptimmune Therapeutics PLCADAP 5,000,250, acquired Open Form 4 filing 0001209191-20-005168
2019-11-12 P, Open-market purchase Galera Therapeutics, Inc.GRTX 4,999,992, acquired Open Form 4 filing 0001209191-19-056068
2019-11-04 P, Open-market purchase Oyster Point Pharma, Inc.OYST 14,960,000, acquired Open Form 4 filing 0001209191-19-055017
2019-08-28 S, Open-market sale Mersana Therapeutics, Inc.MRSN 3,524, disposed Open Form 4 filing 0001209191-20-024272
2019-07-22 P, Open-market purchase Mirum Pharmaceuticals, Inc.MIRM 6,750,000, acquired Open Form 4 filing 0001209191-19-043057
2019-06-24 P, Open-market purchase Genocea Biosciences, Inc.GNCA 9,999,997, acquired Open Form 4 filing 0001209191-19-038959
2019-05-09 P, Open-market purchase Trevi Therapeutics, Inc.TRVI 2 lines 25,000,000, acquired Open Form 4 filing 0001209191-19-029396
2019-05-07 P, Open-market purchase Regulus Therapeutics Inc.RGLS 1,227,640, acquired Open Form 4 filing 0001209191-19-028596
2019-04-08 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 4,956,523, acquired Open Form 4 filing 0001209191-19-023998
2019-03-05 P, Open-market purchase Mersana Therapeutics, Inc.MRSN 15,000,000, acquired Open Form 4 filing 0001209191-19-017378
2019-02-14 P, Open-market purchase Genocea Biosciences, Inc.GNCA 4,688,619, acquired Open Form 4 filing 0001209191-19-011160
2018-12-21 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 448,380, acquired Open Form 4 filing 0001209191-18-064027
2018-12-20 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 326,060, acquired Open Form 4 filing 0001209191-18-064027
2018-12-11 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 121,084, acquired Open Form 4 filing 0001209191-18-062251
2018-12-10 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 51,576, acquired Open Form 4 filing 0001209191-18-061837
2018-12-07 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 232,362, acquired Open Form 4 filing 0001209191-18-061837
2018-12-06 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 54,414, acquired Open Form 4 filing 0001209191-18-061837
2018-11-30 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 142,067, acquired Open Form 4 filing 0001209191-18-060417
2018-11-28 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 48,824, acquired Open Form 4 filing 0001209191-18-060417

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase
Relationships on this page
%, Ten percent owner
Ten percent owner
D, Director
Director

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 76
  • Open-market sale 22
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Florence Anthony A. Jr., insider transactions. Retrieved 2026-08-24 from https://ebomi.com/insider/0001559827

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.